D iabetes mellitus (DM) is of growing concern,
with a prevalence approaching 400 million worldwide and 30 million in the United States (1). Type 2 diabetes mellitus (T2DM), accounting for approximately 95% of DM, is particularly increasing due to insulin resistance from obesity (1).
Both type 1 diabetes mellitus (T1DM) and T2DM
enhance the risk for cardiovascular disease (CVD) by 2-to 6-fold (2) , with mortality arising predominantly from acute thrombotic cardiovascular events (3).
Intensive glycemic control appears to reduce the risk of CVD in T1DM (4) . In contrast, whether there is a beneficial role for intensive glycemic control on CVD in T2DM remains unclear (5) (6) (7) (8) (9) (10) (11) (12) (13) .
Over the past several years it has become clear that alterations in the expression of microribonucleic acid (microRNA or miRNA) contribute to the pathogenesis of diabetes (14) (15) (16) (17) (18) . MicroRNAs are small (w22 nt) regulatory ribonucleic acid (RNA) molecules that functionally modulate the activity of specific messenger RNA targets involved in a wide range of physiological and pathological processes (19) .
Profiling of microRNA expression in patients with diabetes has identified signatures associated with diagnosis, progression, prognosis, and response to treatment (14) . We recently reported that miR-24 is significantly reduced in both T1DM (glycated hemoglobin [HbA1c] >6.5% with absent C-peptide levels) and T2DM (HbA1c >6.5% with normal or higher C-peptide levels) due to hyperglycemia, contributing to endothelial dysfunction (20) . In the present study, we have uncovered a possible unifying mechanism that reconciles the disparate glucose control and cardiovascular disease results between T1DM and T2DM. Excessive insulin in T2DM patients, from the use of insulin therapy on a background of increased insulin, leads to dysregulation of a key protective miRNA: miR-24. These results may present a significant therapeutic dilemma in treating patients with both T2DM and MI (21) (22) (23) . Our study suggests that therapeutic strategies leading to reduced insulin usage, and thus up-regulating miR-24, potentially protect against acute cardiovascular events in T2DM.
METHODS HUMAN STUDIES. C l a m p s t u d y .
A total of 5 individuals with T1DM participated in the study and underwent hyperinsulinemic (2 mU/kg/min) hypoglycemic (glucose w2.8 mmol/l) clamp studies, as previously described (24) Table 1 (26).
STATISTICAL ANALYSES. Statistical analyses were performed using GraphPad Prism 6 (GraphPad Software, La Jolla, California) and SPSS (IBM, Statistics V22, Armonk, New York). Survival curves were analyzed using a log-rank (Mantel-Cox) test. Statistical differences were assessed with unpaired or paired Student's t test using GraphPad Prism 6.
Otherwise, statistical significance was determined using 1-way analysis of variance followed by Board-approved protocol). To confirm that insulin was being infused, plasma insulin levels were measured as well as progression to hypoglycemia (Figures 2A and 2B) . Level of miR-24 decreased despite progressing from hyperglycemia to euglycemia (from 0 to 50 min), supporting that the insulin infusion rather than glucose levels is the direct cause for the reduction in miR-24 level ( Figure 2C ). As further supporting evidence, in patients with T1DM
(where patients are on various forms of exogenous insulin therapy for low insulin levels) we observed an inverse correlation between circulating miR-24 and plasma levels of insulin ( Figure 2D) . In a small pilot (n ¼ 13) and type 2 diabetes mellitus (T2DM) (n ¼ 27), normalized to spiked-in cel-miR-238; analysis of covariance was conducted while adjusting for age and sex. (F) Comparison of human plasma miR-24 levels in healthy subjects (HC) (n ¼ 10) and T2DM without insulin therapy (n ¼ 13) or with insulin therapy (n ¼ 13), normalized to spiked-in cel-miR-238; analysis of covariance was conducted while adjusting for age and sex.
study, we observed an intriguing significant reduction in plasma miR-24 levels in T2DM (n ¼ 27) compared with T1DM patients (n ¼ 13) ( Figure 2E , Supplemental Table 1 ), despite no significant differences in fasting glucose or HbA1c. Almost one-half of T2DM patients were on insulin for glucose control, so we separated the T2DM patients who took insulin.
The lowest miR-24 levels were observed in T2DM patients on insulin therapy ( Figure 2F , Supplemental on myocardial function, we first compared the myocardial infarction size in response to I/R between WT and db/db mice ( Figure 3A) . As mentioned in the previous text, we observed a significantly increased infarct size in diabetic hearts ( Figures 1C to 1E ).
Remarkably, with systemic injection of miR-24 mimic
into db/db mice (2 weeks prior to I/R), we observed significant restoration of cardiac miR-24 levels ( Figure 3B ) (miR-126 served as a control) and a reduction in infarct size ( Figures 3C to 3E ). The increase in infarct size in DM mice (low miR-24) and its rescue by exogenous miR-24 (restoring levels of miR-24) further support a myocardial protective role for miR-24.
Notably, we also observed a significant reduction in plasma insulin level and fasting glucose level with intravenously delivery of miR-24 to db/db mice ( Figures 3F and 3G ), which could contribute to the decrease in infarct size in DM mice.
To demonstrate a cardiac-specific effect, we used a cardiac-specific miR-24 overexpression mouse model. Abbreviations as in Figure 1 .
were remarkably reduced when overexpression of miR-24 with either genetic (miR-24 tg) or pharmacological approaches (miR-24 mimic delivery in vivo) ( Figure 5F ). Taken together, these data further support that OGT, ATG4A, and BIM are direct targets of miR-24, all of which contribute to myocardial I/R injury. Wang et al. Figure 1 .
Wang et al. miR-24 has multiple targets in cardiomyocytes (29) , endothelial cells (28) , and macrophages (35) , all of which are involved in diabetic cardiac complications.
In the heart, miR-24 has been reported to target BIM and junctophilin-2 in cardiomyocytes, and targeting transcription factor GATA2, p21-activated kinase PAK4, and eNOS in endothelial cells (36) . In the vascular system, miR-24 was found to target chitinase 
